UnitedHealthcare Dupilumab (Dupixent) prior authorization requirements (2026)

What UnitedHealthcare generally requires to approve Dupilumab (Dupixent) (CPT J0517), for Commercial (pharmacy benefit; J0517 medical benefit) plans. Yes. UnitedHealthcare generally requires prior authorization for Dupilumab (Dupixent) (CPT J0517).

General reference compiled from public sources, last verified 2026-06-17. This is not a coverage determination or medical advice. Always confirm current requirements with UnitedHealthcare before submitting.

Medical-necessity criteria UnitedHealthcare generally applies

Prior authorization required (OptumRx pharmacy benefit; HCPCS J0517 under the medical benefit). ATOPIC DERMATITIS (prescribed by a dermatologist, allergist, or immunologist): moderate-to-severe chronic atopic dermatitis AND a history of failure, contraindication, or intolerance to TWO of the following topical classes (document drug, date, and/or contraindication): a medium-or-higher-potency topical corticosteroid; a topical calcineurin inhibitor (pimecrolimus, tacrolimus); or crisaborole (Eucrisa). Not used in combination with another biologic immunomodulator or a JAK inhibitor for the same indication. Authorization 12 months; reauthorization requires documented positive clinical response.

Diagnoses that commonly support medical necessity

ICD-10-CM diagnoses frequently associated with medical necessity for Dupilumab (Dupixent). Confirm the covered diagnosis list against the current UnitedHealthcare policy.

L20.9Atopic dermatitis, unspecifiedL20.89Other atopic dermatitis

Commonly required documentation

  • Diagnosis
  • documentation of failure/contraindication/intolerance to TWO topical classes
  • specialist prescriber.

Situations to verify before submitting

UnitedHealthcare may not cover Dupilumab (Dupixent) in these situations. Verify against the current policy rather than assuming a denial:

  • Not covered in combination with another biologic immunomodulator or a JAK inhibitor for the same indication

How to submit

Source

Source: UnitedHealthcare/OptumRx PA policy 2025 P 2116-22 Dupixent (eff 2025-11-01). Requires failure of TWO topical classes (stricter than Cigna/Aetna). Last verified 2026-06-17.

Frequently asked questions

Does UnitedHealthcare require prior authorization for Dupilumab (Dupixent)?

Yes. UnitedHealthcare generally requires prior authorization for Dupilumab (Dupixent) (CPT J0517).

What does UnitedHealthcare require to approve Dupilumab (Dupixent)?

Prior authorization required (OptumRx pharmacy benefit; HCPCS J0517 under the medical benefit). ATOPIC DERMATITIS (prescribed by a dermatologist, allergist, or immunologist): moderate-to-severe chronic atopic dermatitis AND a history of failure, contraindication, or intolerance to TWO of the following topical classes (document drug, date, and/or contraindication): a medium-or-higher-potency topica… Always confirm against the current UnitedHealthcare policy.

How long does a UnitedHealthcare prior authorization take?

Turnaround varies by plan and submission method. Check the UnitedHealthcare portal for current timeframes.

Submitting Dupilumab (Dupixent) to UnitedHealthcare?

Praxigen checks your clinical note against these criteria before you submit and drafts a policy-cited appeal if it is denied. You review and submit; nothing is sent automatically.

How Praxigen worksBook a demo

Other UnitedHealthcare prior authorization requirements

ACL ReconstructionAnterior Cervical Discectomy and FusionArthroplasty (Joint Replacement)Arthroscopic Hip Surgery for Impingement Syndrome Including Labral RepairArthroscopyBariatric SurgeryBariatric Surgery with Obesity DiagnosisBody LengtheningBone Growth Stimulator - Electronic Stimulation or UltrasoundBone Marrow/Stem Cell ProceduresBreast Reconstruction (Non-Mastectomy)Cancer Supportive Care - Antiemetic Drugs

Related guides

Why was my prior authorization denied? Top reasons and how to fix eachHow to write a prior authorization appeal that cites policy